Rigel Pharma's R788 will be partnered in next few months, say Rodman & Renshaw
Following positive R788 positive Ph IIb TASKi2 clinical trial results, Rodman & Renshaw said the drug will be partnered in the next few months. Shares are Outperform rated with a $33 price target.
08:13 EDT RIGL theflyonthewall.com:
Rigel Pharma positive data could lead to lucrative deal, says Thomas Weisel
Thomas Weisel believes the Phase II data for Rigel R788 was positive and the firm believes the data could lead to a lucrative licensing deal for the company. The firm maintains an Outperform rating on Rigel target $30
Thank you! I read your post about earnings, yesterday. I sold at 1.31...Thank you!See you next earnings season :)) Thank you!
07:11 EDT SLM theflyonthewall.com: SLM Corp. target raised to $16 from $13 at FBR Capital
FBR raised its estimates and target price for SLM to reflect improving student loan spreads and the earnings potential from the servicing contract with the Department of Education. The firm reiterates an Outperform rating on the stock.
trade condition is T...last exchange is TH...which means third party
There is not ususally a trade condition. T means hand written by the market maker.
Form T...hand written...late print. That was an intraday trade. Somebody either bought or sold at that price and had to fight the market maker. The trade condition is T. That means hand written. The market maker gave them their trade.
That was in Random Musings in this article today....
By Jim Cramer
6/25/2009 12:18 PM EDT
Click here for more stories by Jim Cramer
JP Morgan gave SLM an Overweight and $14 target.
Cramer article today..
"Sallie Mae (SLM - commentary - Trade Now) is not done. It is worth double figures. Hold on to it!"
Sorry, you have to have a sub to Real Money, but here is the link, if you do.
Thnk you, GHM got an upgrade today...target 15 from 14
Graham upgraded to Buy from Hold at Roth Capital
Roth Capital upgraded Graham citing the resumption of the Jubail, Saudi Arabia project. The firm believes the company is well positioned for additional large refining projects. Target to $15 from $14. :theflyonthewall
Thank you, Two upside earnings surprises now :))
Fonar trades up over 200% after reporting Q3 results (3.30 +2.23)
This morning FONR is trading up ~211% on above average volume after reporting Q3 results. This morning the co announced its earnings for the third quarter of fiscal 2009 ending March 31, 2009. For Q3 the co reports net income of $730,000 vs a loss of $2.7 mln YoY. Revenues increased 39.5% to $11.3 mln vs $8.1 mln YoY. The co said "We are delighted that the Company has once again become profitable. In fact we now have two straight quarters of income greater than $700,000. There are several reasons for this. While 2008 was a difficult year, we initiated an aggressive cost-cutting program. Costs and expenses have been reduced in most categories but most significantly in our selling, general and administrative expenses. Overall, S, G & A was reduced 36.0% from $15.5 mln for the nine months ending March 31, 2008 to $10.0 mln for the most current nine month period.